Market Overview

Hemochromatosis | A Drug Pipeline Analysis Report 2018 | Technavio


Technavio has announced their latest drug pipeline analysis report on hemochromatosis.
The report includes a detailed analysis of the pipeline molecules under
investigation within the defined data collection period to treat

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for hemochromatosis, including ...

Technavio has published a new report on the drug development pipeline for hemochromatosis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing

Hemochromatosis: Market overview

Hemochromatosis is a disorder in which the body simply loads too much
iron from the diet. It occurs either by mutations in the gene or by
other medical conditions such as anemia, chronic liver disease, and
kidney dialysis. Various symptoms of the disease include abdominal pain,
fatigue, joint pain, liver failure, and weakness.

According to a senior market research analyst at Technavio, "The
disease occurs mostly due to the mutations in the C282Y and TMPRSS6
genes in the body. There are different types of hemochromatosis
including hereditary hemochromatosis, juvenile hemochromatosis, neonatal
hemochromatosis, and secondary hemochromatosis. Eventually, with the
rising incidences of the syndrome, the need for the drug development for
the treatment of hemochromatosis is likely to surge considerably in the
forthcoming years."

Hemochromatosis: Segmentation analysis

This drug pipeline analysis report segments the hemochromatosis market
based on therapies employed (monotherapy), RoA (oral, subcutaneous, and
parenteral), therapeutic modality (small molecule), targets (TMPRSS6,
hepcidin, iron, and ferroportin), MoA (TMPRSS6 inhibitor, hepcidin
stimulants, iron chelator, and ferroportin inhibitor), geographical
segmentation (the US, Spain, Switzerland, and Belgium) and recruitment
status (recruiting). It provides an in-depth analysis of the prominent
factors influencing the market, including drivers, opportunities,
trends, and industry-specific challenges.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team

View Comments and Join the Discussion!